Pharmaceutical Documentation Enters a New Era of Innovation
The future of pharmaceutical documentation is here – faster, smarter and compliant. That’s what World Pharma Today learnt from its recent interview with Docuvera. Striking the right chord between regulatory compliance and automation, Docuvera has indeed changed the way pharmaceutical documentation is being analyzed and executed. 1. How does Docuvera’s AI-driven approach transform the erstwhile traditional pharmaceutical […]
How Language Barriers Impact Non-Native English Speakers in Healthcare
Language barriers create significant challenges for non-native English speakers in healthcare settings. In the United States, English is the primary language, which complicates communication for non-English-speaking patients. These patients often struggle to describe symptoms, understand instructions, and navigate the healthcare system effectively. Miscommunication can lead to misdiagnosis, improper treatment, and poor health outcomes. As diversity […]
Steriline's Advanced Filling Innovations Exhibited At Interphex 2025
New York City, March 25, 2025 – Steriline, a well-established European manufacturer of highly specialized robotic filling machines and complete aseptic filling/finishing lines, will attend Interphex, the leading global pharmaceutical and biotechnology event that fosters collaborations and provides a comprehensive view of advancements in the pharmaceutical industry. The company will welcome visitors on April 1-3, 2025 at stand 2537 in the Javits Center, NYC, […]
FDA Approval of AMVUTTRA for ATTR Amyloidosis
Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics, has announced U.S. FDA approval of AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. This approval makes AMVUTTRA the first and only U.S. FDA-approved therapeutic to address both cardiomyopathy and polyneuropathy (hATTR-PN) in ATTR amyloidosis. ATTR-CM is […]
Rina-S Shows Promise in Advanced Ovarian Cancer
Genmab has reported encouraging findings from the Phase 2 RAINFOL-01 trial of rinatabart sesutecan (Rina-S®), an experimental folate receptor-alpha (FRα)-targeted, TOPO1 antibody-drug combination (ADC). Data from the B1 cohort of the trial showed encouraging antitumor efficacy in highly pre-treated patients with advanced ovarian cancer (OC) independent of FRα expression levels. Rina-S 120 mg/m2 Q3W showed […]
Coronado Research Announce the Appointment of Gary Lyons as EVP Medical Affairs
London, UK: Coronado Research has appointed Gary Lyons as EVP Medical Affairs. Gary is a seasoned senior Medical Affairs leader with extensive strategic and operational implementation experience across the industry and product lifecycle. He has previously led agency business units and built strategic teams focused on delivering outstanding medical communication services at global and local levels – […]
Global GenAI study reveals optimism and opportunities for healthcare and life sciences
Marlow, UK – Generative AI (GenAI) is at the forefront of global innovation in both healthcare and life sciences. To better understand how technology is being used, data and AI leader SAS and Coleman Parkes Research conducted a global, cross-industry survey of 237 life sciences and pharma leaders and 240 healthcare leaders who are decision makers […]
Pharma Support Powers Sofinnova Biotech Acceleration Fund
Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong Pharma Support European life sciences investment firm Sofinnova Partners has announced the final close of its second biotech acceleration fund, raising €165 million and surpassing its original target. The fund, Sofinnova Biovelocita II, now holds the title as the largest pan-European initiative of its kind, with […]
Shilpa Biologicals Pvt Ltd signs strategic development partnership with mAbTree Biologics AG for a novel immuno-oncology asset
Basel Switzerland, and Karnataka India: mAbTree Biologics AG has signed an exclusive co-development and commercialization partnership with Shilpa Biologicals Pvt Ltd. (a fully owned subsidiary of Shilpa Medicare Limited) for its novel biologic asset [a checkpoint inhibitor] for immuno-oncological applications. Under the terms of the strategic agreement, Shilpa Biologicals will support both development – including clinical studies – as […]
Sirio Launches Global Research Institute for Longevity Studies [SIA]
Research Institute to advance nutraceutical product development across four core research areas SIRIO Pharma (SIRIO) – the global nutraceutical contract development and manufacturing organization (CDMO) – announces the launch of the Sirio Institute for Anti-Ageing (SIA) at the 2025 Boao Health Food Science Conference and Expo. The Institute aims to advance anti-ageing science and accelerate the development and commercialization of […]
